shutterstock_1174421515_eyesonmilan
eyesonmilan / Shutterstock.com
22 August 2019Americas

Gilead challenges US govt patents on HIV drug Truvada

Gilead Sciences, the maker of HIV drug Truvada (emtricitabine/tenofovir), has asked the US Patent and Trademark Office (USPTO) to review patents granted to the government covering preventative use of the drug.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
27 January 2020   Gilead Sciences has accused a US government agency of withholding information from the US Patent and Trademark Office when filing two patents for HIV pre-exposure prophylaxis.
Americas
21 February 2020   Gilead Sciences has failed in its efforts to have US government patents covering the use of HIV drugs as pre-exposure prophylaxis invalidated.
Americas
22 September 2020   Biopharmaceutical company Gilead is being sued for allegedly scheming to prevent a generic rival from releasing a competing version of its HIV drug Truvada, according to a class action lawsuit filed by investors in the drug manufacturer.

More on this story

Americas
27 January 2020   Gilead Sciences has accused a US government agency of withholding information from the US Patent and Trademark Office when filing two patents for HIV pre-exposure prophylaxis.
Americas
21 February 2020   Gilead Sciences has failed in its efforts to have US government patents covering the use of HIV drugs as pre-exposure prophylaxis invalidated.
Americas
22 September 2020   Biopharmaceutical company Gilead is being sued for allegedly scheming to prevent a generic rival from releasing a competing version of its HIV drug Truvada, according to a class action lawsuit filed by investors in the drug manufacturer.

More on this story

Americas
27 January 2020   Gilead Sciences has accused a US government agency of withholding information from the US Patent and Trademark Office when filing two patents for HIV pre-exposure prophylaxis.
Americas
21 February 2020   Gilead Sciences has failed in its efforts to have US government patents covering the use of HIV drugs as pre-exposure prophylaxis invalidated.
Americas
22 September 2020   Biopharmaceutical company Gilead is being sued for allegedly scheming to prevent a generic rival from releasing a competing version of its HIV drug Truvada, according to a class action lawsuit filed by investors in the drug manufacturer.